HXBM (Helix Biomedix) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2012)


What is Helix Biomedix LT-Debt-to-Total-Asset?

Helix Biomedix HXBM LT-Debt-to-Total-Asset is 0.00 as of Sep. 2012.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Helix Biomedix's long-term debt to total assests ratio for the quarter that ended in Sep. 2012 was 0.00.

Helix Biomedix's long-term debt to total assets ratio stayed the same from Sep. 2011 (0.00) to Sep. 2012 (0.00).

Helix Biomedix  (OTCPK:HXBM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Helix Biomedix LT-Debt-to-Total-Asset Related Terms

Helix Biomedix LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Helix Biomedix's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix Biomedix LT-Debt-to-Total-Asset Chart

Helix Biomedix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.11 3.15 0.00 0.00

Helix Biomedix Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix Biomedix LT-Debt-to-Total-Asset Calculation

Helix Biomedix's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2011 is calculated as

LT Debt to Total Assets (A: Dec. 2011 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2011 )/Total Assets (A: Dec. 2011 )
=0/2.975
=0.00

Helix Biomedix's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2012 is calculated as

LT Debt to Total Assets (Q: Sep. 2012 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2012 )/Total Assets (Q: Sep. 2012 )
=0/1.702
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Helix Biomedix (HXBM) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2012. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Helix Biomedix and its competitors.
Is Helix Biomedix's LT-Debt-to-Total-Asset too high?
Helix Biomedix's current LT-Debt-to-Total-Asset is 0.00.
How does Helix Biomedix's LT-Debt-to-Total-Asset compare to XBIO and CBLI?
Helix Biomedix's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Helix Biomedix and its competitors. Helix Biomedix's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix Biomedix stock overvalued right now?
Helix Biomedix (HXBM) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Helix Biomedix (HXBM), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix Biomedix Business Description

Address 19125 North Creek Parkway, Suite 120, Bothell, WA, USA, 98011
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.